BRAK LABS Peptide research, plainly written

documented protocols

BPC-157: what is documented about dosing

What published work gave, in which species and by which route, reported as a record rather than as a protocol.

Last Reviewed Editorial policy Methodology

Published work on BPC-157 records what was given to rats, mice and dogs, and to about 80 people across five studies, in the model or the clinic each one used. Roughly 116 people were randomized or enrolled in those five, and about 80 of them were in an arm that received the compound. That record is set out below with the species and the route named on every line.

No study has established an amount for a person, on any route. The figures that circulate in community write-ups and on vendor pages are extrapolations from rodent experiments or have no traceable origin, and this page does not republish them.

What this page does instead is name the source class on every line and state what the underlying figure actually was: an animal regimen scaled to body weight, a clinic's compounded preparation, or a formulation loading. None of those converts into an amount for anybody.

Not medical advice

This page reports what has been documented about a compound. It is not medical advice, not a diagnosis, not a dosing protocol, and not a recommendation to obtain or use anything described here. Talk to a licensed clinician about anything concerning your health. Read the full disclaimer.

Reviewed against editorial standards Updated

What this page reports, and what it does not

We report what has been documented. We do not prescribe what should be done.

Nothing here is a dosing recommendation. Statements about dosing reflect community and research reports only.

No trial established an amount of BPC-157 for a person. Most of the rows below record what a published study gave to its animals or its cells, in the model that study built, with the species and the route named on the line. One row records that other figures circulate in community write-ups, and that this site does not republish them. Nothing here is a protocol, nothing here is scaled for a person, and this site publishes no preparation steps, no administration technique and no equipment. The reasoning is in the editorial policy.

Commonly cited protocols (extrapolated, not validated)

What published studies gave, in which species and by which route, and what circulates elsewhere. The source class is named on every row, and none of it is a clinical protocol
StudyWhat was givenFrequencyDurationNotes
Rat tendon, muscle and ligament models. Staresinic 2003, Krivic 2006, Staresinic 2006, Novinscak 2008, Cerovecki 2010, Japjec 2021 [4] [5] [7] [8] [11] [9]A body-weight-scaled regimen reported per study, given into the abdominal cavity in most armsPer each study protocol14 to 90 days depending on the modelYoung healthy rats with an injury created by a surgeon. A rodent amount scaled to body weight does not convert to a person, and this site does not print the ladder those studies used
Rat models using oral, drinking-water or topical arms. Novinscak 2008, Cerovecki 2010, Japjec 2021, Matek 2025 [8] [11] [9] [10]The same body-weight-scaled regimens delivered by mouth, in drinking water or as a creamPer each study protocol14 to 90 daysThe underreported half of the animal file. Several of these studies reported the same direction from a non-injected arm as from the injected one
Rat and dog pharmacokinetics and toxicology. He 2022, Xu 2020 [24] [25]Ascending intramuscular levels and a single intravenous level, plus a 28-day repeat-dose regimenSingle and repeated, per protocolSingle dose to 28 daysThe only formal exposure work that exists. It is where the half-life figure and the coagulation and liver signals both come from
Human rectal course, unpublished. Veljaca 2002 and 2003 [32]Four ascending levels of a rectal preparation in healthy volunteersPer the study protocol, in two stages with a washout between themAbout two weeksThe only human dose-ranging work ever done, and it exists as two conference abstracts read through FDA's review. The compound was not detected in plasma at any level
Human rectal course, ulcerative colitis. Ruenzi 2005 [32]A fixed rectal preparation against placeboPer the study protocolTwo weeksThe only randomized efficacy study. The amount and schedule are in FDA's reprinting of the abstract and are not published here, because a two-week course in a colitis trial is not a starting point for anything and printing it would supply one
Human clinic preparations. Lee 2021, Lee 2024, Lee 2025 [26] [27] [28]Compounded preparations obtained from 503A pharmacies, given by injection into a knee, into the bladder wall at cystoscopy, or by intravenous infusionPer each published series: a short course in the joint series, a single procedure in the bladder series, and two consecutive days in the infusion reportOne visit to two daysThree different clinical routes and three different preparations, none of them the presentation sold to consumers. The amounts are in the papers and are not reproduced here
Community write-ups and vendor pagesFigures circulate. This site does not republish themFigures circulateFigures circulateNo trial established an amount for a person by the route those figures describe, because no study of any design has used that route in a person. Republishing a figure would supply an instruction with a hedge around it, which is the thing this site exists not to do

Two things in that table deserve pulling out. The first is that the marketed presentation, a lyophilised powder in a vial reconstituted and injected under the skin, appears nowhere in it. Not in an animal study, not in a clinic report, not in a registration that has read out.

The second is that a body-weight-scaled rodent regimen is not convertible into a human amount even in principle. Interspecies scaling is unreliable between two mammals given the same route, and none of the animal work here used the route in question. Arithmetic performed on those numbers produces a figure with the appearance of a derivation and none of the content of one.

Our takeThe most useful sentence anyone can write about BPC-157 amounts is that the way it is actually used has never been studied in any species. Everything in circulation is arithmetic stacked on a route nobody has tested.

Main routes people compare

Systemic injection: what was used and what is sold

Nearly all of the rodent efficacy work delivered the peptide into the abdominal cavity, which is a route used in animal research for reliable systemic exposure and is not a route used in people [4] [7] [8]. The formal pharmacokinetic study used intravenous and intramuscular administration instead, and reported a plasma half-life under 30 minutes in both species it tested [24].

Subcutaneous injection, which is how the compound is sold, appears in none of them. It has not been studied in a person on any endpoint, and it has not been studied in an animal efficacy model either.

This site publishes no preparation procedure, no administration technique and no equipment, on any route. The reasoning is set out in the editorial policy. [Animal] [4] [7] [8] [24]

Oral and gut-directed

The oral arms are the part of this literature most often left out of summaries. Several rodent studies ran a per-oral or drinking-water arm alongside the injected one and reported the same direction from both, in muscle, in the myotendinous junction and in ligament [9] [10] [11]. The colitis work used intragastric and intracolonic delivery as well as intraperitoneal [12] [13].

That literature also carries the clearest published route negative for this compound. In the 1995 colitis study, intraperitoneal administration reduced necrosis and colonic myeloperoxidase in a dose-dependent way, and intracolonic administration reduced neither significantly [12]. Getting a peptide to the tissue is not the same problem as getting it into the animal, and this file says so from inside its own data. [Animal] [9] [10] [11] [12] [13]

Rectal, the only human dose-ranging route

Every human dose-ranging experiment ever run on this compound used a rectal preparation, in the two unpublished studies from the original development programme [32]. That was a deliberate choice for an ulcerative colitis programme and it is why the human record looks nothing like the retail market.

The result worth carrying from those studies is the pharmacokinetic one. The compound was not detected in plasma, with most concentrations below the limit of quantification. Whatever a rectal preparation was doing in those volunteers, it was not producing measurable systemic exposure with the assay available. [Human RCT] [32]

Local clinical routes

The two published clinic series used local administration: into a knee joint in the 2021 chart review and around inflamed bladder wall at cystoscopy in the 2024 pilot [26] [27]. Both used material compounded by a 503A pharmacy.

Those are procedures performed by a clinician under imaging or direct vision, and this page describes them as a record of what was done rather than as anything a reader could act on. No preparation, technique or equipment appears here. [Human open-label] [26] [27]

What is said about cycle length and timing

Cycle lengths, loading phases and washout periods circulate widely for BPC-157, and none of them came from a study. The rodent experiments ran for the length of the created injury: 14 days in the transected tendon and crushed muscle models, 21 days in the tendon-to-bone model, 42 days in the myotendinous work, 72 and 90 days in the two longest muscle studies. The one human dose-ranging protocol ran about two weeks including its washout.

Long-term exposure is the gap underneath all of that. The only formal repeat-dose toxicology ran 28 days, and FDA records that longer studies were unavailable to show whether the signals it found persist or whether new ones appear.

Timing claims, with food or without, before training or after, have the same status. No pharmacokinetic study in a person exists on any route that could support or contradict them.

Where a figure has a source, this page names it. Where it does not, this page says so rather than repeating it with a disclaimer attached.

Talk to a licensed clinician about anything concerning your health.

Frequently asked questions

Is there a documented BPC-157 dose?

Not for a person by the route it is sold. The only human dose-ranging work ever done used a rectal preparation in an ulcerative colitis programme, exists as two conference abstracts, and did not detect the compound in plasma. Everything else documented is what individual animal studies gave to rats and dogs, scaled to body weight, and those figures are properties of those experiments.

Why does this page not list the figures that appear on vendor sites?

Because none of them traces to a study in a person by the route they describe, and publishing one with a hedge attached still supplies an instruction. This site links to storefronts under common ownership, which makes anything published here readable as labelling for what those storefronts sell, so the rule is stricter here than at an independent publisher. The reasoning is on the editorial policy page.

Which route has the most published work behind it?

Injection into the abdominal cavity in rats, by a wide margin, and it is a laboratory route rather than a clinical one. After that, oral and drinking-water arms in several of the same rodent studies, then the rectal preparations in the two unpublished human studies, then three different local clinical routes in three small published series. Subcutaneous injection, the retail route, has no published work in any species.

Does this site publish preparation steps?

No. No preparation procedure, no administration technique and no equipment appears anywhere on this site, for any compound. That is a standing rule rather than a judgement about BPC-157, and the reasoning is on the editorial policy page.

How long did the studies run?

The rodent injury models ran 14 to 90 days, with one spinal cord study followed to 360. The formal repeat-dose toxicology ran 28 days in rats and dogs. The human studies ran two weeks at most, and two of the three published clinic reports covered a single visit.

Is oral BPC-157 absorbed?

No human study has measured it, on that route or any other. Several rodent studies ran an oral or drinking-water arm and reported the same direction as their injected arm, which is a functional observation rather than an absorption measurement. The one formal pharmacokinetic study used intravenous and intramuscular administration and did not test the oral route.

References

  1. Sikiric P, Seiwerth S, Brcic L, Blagaic AB, Zoricic I, Sever M, Klicek R, Radic B, Keller N, Sipos K, Jakir A, Udovicic M, Tonkic A, Kokic N, Turkovic B, Mise S, Anic T. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology. 2006. PMID 17186181 DOI 10.1007/s10787-006-1531-7
  2. Sikiric P, Petek M, Rucman R, Seiwerth S, Grabarević Z, Rotkvić I, Jagić V, Turković B, Mildner B, Duvnjak M. The significance of the gastroprotective effect of body protection compound (BPC): modulation by different procedures. Acta Physiol Hung. 1992. PMID 1345210
  3. Sikiric P, Seiwerth S, Grabarevic Z, Petek M, Rucman R, Turkovic B, Rotkvic I, Jagic V, Duvnjak M, Mise S. The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promotors and gut peptides. Life Sci. 1994. PMID 7904712 DOI 10.1016/0024-3205(94)00796-9
  4. Staresinic M, Sebecic B, Patrlj L, Jadrijevic S, Suknaic S, Perovic D, Aralica G, Zarkovic N, Borovic S, Srdjak M, Hajdarevic K, Kopljar M, Batelja L, Boban-Blagaic A, Turcic I, Anic T, Seiwerth S, Sikiric P. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003. PMID 14554208 DOI 10.1016/S0736-0266(03)00110-4
  5. Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006. PMID 16583442 DOI 10.1002/jor.20096
  6. Biçer O, Adanir O, Güleryüz Y, Balci EC, Dinçel YM, Yenigün MY, Aydin C, Bayrak BY. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026. PMID 42542926 DOI 10.52312/jdrs.2026.2951
  7. Staresinic M, Petrovic I, Novinscak T, Jukic I, Pevec D, Suknaic S, Kokic N, Batelja L, Brcic L, Boban-Blagaic A, Zoric Z, Ivanovic D, Ajduk M, Sebecic B, Patrlj L, Sosa T, Buljat G, Anic T, Seiwerth S, Sikiric P. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. J Orthop Res. 2006. PMID 16609979 DOI 10.1002/jor.20089
  8. Novinscak T, Brcic L, Staresinic M, Jukic I, Radic B, Pevec D, Mise S, Tomasovic S, Brcic I, Banic T, Jakir A, Buljat G, Anic T, Zoricic I, Romic Z, Seiwerth S, Sikiric P. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today. 2008. PMID 18668315 DOI 10.1007/s00595-007-3706-2
  9. Japjec M, Horvat Pavlov K, Petrovic A, Staresinic M, Sebecic B, Buljan M, Vranes H, Giljanovic A, Drmic D, Japjec M, Prtoric A, Lovric E, Batelja Vuletic L, Dobric I, Boban Blagaic A, Skrtic A, Seiwerth S, Predrag S. Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats. Biomedicines. 2021. PMID 34829776 DOI 10.3390/biomedicines9111547 PubMed indexes the last author of this paper as Predrag S, which is Sikiric P with the name parts inverted at the source. The author list here is transcribed from that record and is not corrected by hand, so a reader counting the shared senior author across this page's reference list finds sixteen literal matches for Sikiric P and this seventeenth under the inverted form.
  10. Matek D, Matek I, Staresinic E, Japjec M, Bojanic I, Boban Blagaic A, Beketic Oreskovic L, Oreskovic I, Ziger T, Novinscak T, Krezic I, Strbe S, Drinkovic M, Brkic F, Popic J, Skrtic A, Seiwerth S, Staresinic M, Sikiric P, Brizic I. Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats. Pharmaceutics. 2025. PMID 39861766 DOI 10.3390/pharmaceutics17010119
  11. Cerovecki T, Bojanic I, Brcic L, Radic B, Vukoja I, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010. PMID 20225319 DOI 10.1002/jor.21107
  12. Veljaca M, Lesch CA, Pllana R, Sanchez B, Chan K, Guglietta A. BPC-15 reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. J Pharmacol Exp Ther. 1995. PMID 7815358
  13. Klicek R, Kolenc D, Suran J, Drmic D, Brcic L, Aralica G, Sever M, Holjevac J, Radic B, Turudic T, Kokot A, Patrlj L, Rucman R, Seiwerth S, Sikiric P. Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. J Physiol Pharmacol. 2013. PMID 24304574
  14. Vuksic T, Zoricic I, Brcic L, Sever M, Klicek R, Radic B, Cesarec V, Berkopic L, Keller N, Blagaic AB, Kokic N, Jelic I, Geber J, Anic T, Seiwerth S, Sikiric P. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. Surg Today. 2007. PMID 17713731 DOI 10.1007/s00595-006-3498-9
  15. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011. PMID 21030672 DOI 10.1152/japplphysiol.00945.2010
  16. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014. PMID 25415472 DOI 10.3390/molecules191119066
  17. Tkalcević VI, Cuzić S, Brajsa K, Mildner B, Bokulić A, Situm K, Perović D, Glojnarić I, Parnham MJ. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. Eur J Pharmacol. 2007. PMID 17628536 DOI 10.1016/j.ejphar.2007.05.072
  18. Seveljević-Jaran D, Cuzić S, Dominis-Kramarić M, Glojnarić I, Ivetić V, Radosević S, Parnham MJ. Accelerated healing of excisional skin wounds by PL 14736 in alloxan-hyperglycemic rats. Skin Pharmacol Physiol. 2006. PMID 16785777 DOI 10.1159/000093982
  19. Hrelec M, Klicek R, Brcic L, Brcic I, Cvjetko I, Seiwerth S, Sikiric P. Abdominal aorta anastomosis in rats and stable gastric pentadecapeptide BPC 157, prophylaxis and therapy. J Physiol Pharmacol. 2009. PMID 20388960
  20. Gojkovic S, Krezic I, Vrdoljak B, Malekinusic D, Barisic I, Petrovic A, Horvat Pavlov K, Kolovrat M, Duzel A, Knezevic M, Kasnik Kovac K, Drmic D, Batelja Vuletic L, Kokot A, Boban Blagaic A, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in rats. World J Gastrointest Pathophysiol. 2020. PMID 32226643 DOI 10.4291/wjgp.v11.i1.1
  21. Stupnisek M, Franjic S, Drmic D, Hrelec M, Kolenc D, Radic B, Bojic D, Vcev A, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157 reduces bleeding time and thrombocytopenia after amputation in rats treated with heparin, warfarin or aspirin. Thromb Res. 2012. PMID 21840572 DOI 10.1016/j.thromres.2011.07.035
  22. Tudor M, Jandric I, Marovic A, Gjurasin M, Perovic D, Radic B, Blagaic AB, Kolenc D, Brcic L, Zarkovic K, Seiwerth S, Sikiric P. Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. Regul Pept. 2010. PMID 19931318 DOI 10.1016/j.regpep.2009.11.012
  23. Perovic D, Kolenc D, Bilic V, Somun N, Drmic D, Elabjer E, Buljat G, Seiwerth S, Sikiric P. Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. J Orthop Surg Res. 2019. PMID 31266512 DOI 10.1186/s13018-019-1242-6
  24. He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, Zhang W, Wang S, Wang Z, Hao Q, Zhang C, Gao Y, Gu J, Zhang Y, Li W, Li M. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022. PMID 36588717 DOI 10.3389/fphar.2022.1026182
  25. Xu C, Sun L, Ren F, Huang P, Tian Z, Cui J, Zhang W, Wang S, Zhang K, He L, Zhang W, Zhang C, Hao Q, Zhang Y, Li M, Li W. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020. PMID 32334036 DOI 10.1016/j.yrtph.2020.104665
  26. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021. PMID 34324435
  27. Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024. PMID 39325560
  28. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. PMID 40131143
  29. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMID 40756949 DOI 10.1177/15563316251355551
  30. Grubisic MM, Strbe S, Barisic I, Balenovic D, Stambolija V, Lozic M, Ostojic SB, Oreskovic I, Zizek H, Brcic K, Coric L, Staresinic M, Blagaic V, Oreskovic LB, Halle ZB, Matek D, Soldo D, Grizelj B, Blagaic AB, Skrtic A, Sikiric P, Seiwerth S. Withdrawn: Stable Gastric Pentadecapeptide BPC 157 as a Therapy of Severe Electrolyte Disturbances in Rats. Curr Neuropharmacol. 2025. PMID 39865815 DOI 10.2174/011570159X349612241205065330 Flagged by PubMed as a Retracted Publication. The publisher's own notice says the article has been withdrawn at the author's request, which is the wording the title carries.
  31. Mateescu DM, Gavrilescu DM, Constantinescu FE, Oancea C, Ilie AC, Folescu R, Popa MD, Iurciuc S, Muresan CO, Enache A. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026. PMID 42198317 DOI 10.3390/pharmaceutics18050625
  32. US Food and Drug Administration. FDA briefing document for BPC-157-related bulk drug substances, Pharmacy Compounding Advisory Committee, 23 and 24 July 2026. 68 pages. Carries FDA's reprinting of the Ruenzi 2005 and Veljaca 2002 and 2003 meeting abstracts, the characterization findings, and the recommendation against listing. FDA advisory committee materials. 2026. Source document
  33. US Food and Drug Administration. July 23, 2026 Meeting of the Pharmacy Compounding Advisory Committee: FDA presentations. 149 pages. Carries the pharmacology limitations, the animal pharmacokinetics, the 28-day toxicology signals, the three FAERS reports and the clinical safety conclusion. FDA advisory committee materials. 2026. Source document
  34. US Food and Drug Administration. Questions for PCAC regarding whether FDA should include certain bulk drug substances on the 503A Bulks List, 23 and 24 July 2026. BPC-157 free base and BPC-157 acetate are the first two votes of the 23 July morning session. FDA advisory committee materials. 2026. Source document
  35. US Food and Drug Administration. Pharmacy Compounding Advisory Committee; notice of meeting; establishment of a public docket; request for comments. Docket No. FDA-2025-N-6895. The chart of uses records the use evaluated for BPC-157 free base and BPC-157 acetate as ulcerative colitis. Federal Register, document 2026-07361, 91 FR 20465. 2026. Source document
  36. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Page content current as of 22 April 2026. BPC-157 appears in the second table, bulk drug substances nominated but withdrawn, and not in the active category 2 table. FDA human drug compounding. 2026. Source document
  37. US Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee, meeting page and materials index. Page content current as of 6 August 2026 and read on 8 August 2026: briefing documents, agenda, roster, questions, webcast information and two presentation decks are posted, and no minutes, transcript or vote record is. FDA advisory committee calendar. 2026. Source document
  38. PharmaCotherapia d.o.o. Phase I, pilot study in healthy volunteers to assess the safety and pharmacokinetics of PCO-02, whose active ingredient is BPC-157, a pentadecapeptide from a gastric source (NCT02637284). Randomized, quadruple-masked, placebo-controlled, 42 estimated, single site in Tijuana. Status unknown; first posted and last updated 22 December 2015; no results posted. ClinicalTrials.gov. 2015. Source document
  39. Hudson Biotech. A randomized, double-blind, placebo-controlled phase 2 trial of pentadecapeptide BPC 157 for accelerated repair of acute grade II hamstring strain confirmed by MRI (NCT07437547). Registered as recruiting, 120 estimated, single site at Peking University Shenzhen Hospital, actual start 2 February 2026, primary completion estimated 14 February 2027; no results posted. Read in full 8 August 2026, together with the sponsor account below. ClinicalTrials.gov. 2026. Source document
  40. Parlay Wellness, with Citruslabs. A clinical trial to evaluate the effects of peptide gummies on markers of inflammation, physical performance, and recovery (NCT07752381). Single-arm, open-label, no randomization or masking, 40 actual participants, site in Las Vegas. Completed 1 November 2025 and first posted 7 August 2026; no results posted. ClinicalTrials.gov. 2026. Source document
  41. US National Library of Medicine. ClinicalTrials.gov registry, API v2, read in full on 8 August 2026. An intervention and free-text search for BPC-157 and its variants returns three records: NCT02637284, NCT07437547 and NCT07752381. A sponsor search for Hudson Biotech returns eight records: NCT07437547, NCT07437560, NCT07437586, NCT07467447, NCT07481734, NCT07481747, NCT07487363 and NCT07505745. Three of the eight describe themselves in their own registered text as an example, a mock study or a fictional study, and two carry Eli Lilly protocol identifiers for Lilly molecules. ClinicalTrials.gov. 2026. Source document
  42. World Anti-Doping Agency. The 2026 Prohibited List, international standard, effective 1 January 2026. 26 pages. BPC-157 is named on the face of class S0 at page 4 and carries its own index entry. WADA. 2026. Source document
  43. US Department of Defense, Operation Supplement Safety. Ingredient and substance index, and the article BPC-157: a prohibited peptide and an unapproved drug found in health and wellness products, posted 29 April 2025. Index checked 8 August 2026: the BPC-157 entry reads that BPC-157 is on the DoD Prohibited Dietary Supplement Ingredients list, with a status label of Prohibited. OPSS, Uniformed Services University. 2026. Source document